SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Communiqués Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Actions

600196

CNE000000X38

Cours en clôture Shanghai S.E. Autres places de cotation 00:00:00 17/07/2024			Varia. 5j.	Varia. 1 janv.
23,04 ^CNY	+1,63 %		+3,92 %	-7,95 %

12/07	Fosun Pharma reçoit des offres pour une offre alternative d'actions liée à l'offre de fusion de Henlius	MT
08/07	Le traitement anticancéreux de Shanghai Fosun Pharmaceutical (Group) reçoit le feu vert de la NMPA pour les essais cliniques	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	15/04	AQ
Shanghai Fosun Pharmaceutical : Fosun Pharma and Insightec Establish Joint Venture to Expand Global Access to Focused Ultrasound Treatment for Neurological Diseases	12/12	PU
Marubeni Corporation - Expansion of Pharmaceutical Business Initiatives	26/04/23	AQ
Fosun Pharma’s 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public	30/03/23	PU
Shanghai Fosun Pharmaceutical : COMIRNATY® Bivalent COVID-19 Vaccine is Officially Approved as Regular Imported Vaccine by the Pharmaceutical Administration Bureau of Macao SAR	20/01/23	PU
Syneos Health Announces Partnership with Fosun Pharma USA to Launch SerplulimabRelationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial Solutions	12/01/23	AQ
Syneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab	11/01/23	AQ
Shanghai Fosun Pharmaceutical : Self-Paid Vaccination Service for Bivalent COVID-19 Vaccine COMIRNATY® is Officially Provided in Hong Kong, Offering More Vaccine Options for People in Need	06/01/23	PU
Shanghai Fosun Pharmaceutical : Fosun Pharma Announces Results for the First Three Quarters of 2022	30/10/22	PU
Shanghai Fosun Pharmaceutical : Fosun Pharma’s MSCI ESG Rating Upgraded to A	13/10/22	PU
Neovii and Fosun Pharma Enter into an Exclusive Agreement	08/09/22	AQ
Shanghai Fosun Pharmaceutical : Fosun Pharma Topped the 2022 Fortune China ESG Impact List	25/08/22	PU
Shanghai Fosun Pharmaceutical : Fosun Pharma and Amgen Announce Collaboration to Accelerate Two Innovative Medicines Benefitting Chinese Patients	27/06/22	PU
Shanghai Fosun Pharmaceutical : Continuously Promoting Innovation and Internationalization Fosun Pharma Presents at 2022 BIO International Convention	17/06/22	PU
Shanghai Fosun Pharmaceutical : VOLUNTARY ANNOUNCEMENT - ENTERING INTO SALE AND PURCHASE AGREEMENTS （H SHARES）	06/06/22	PU
Shanghai Fosun Pharmaceutical : MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2022(H SHARES)	02/06/22	PU
Shanghai Fosun Pharmaceutical : (1) RE-APPOINTMENT OF CHAIRMAN AND VICE CHAIRMAN (2) APPOINTMENT OF CO-CHAIRMAN (3) APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND CO-CHIEF EXECUTIVE OFFICER AND (4) CHANGE IN BOARD COMMITTEE COMPOSITION	01/06/22	PU
Shanghai Fosun Pharmaceutical : Axicabtagene Ciloleucel - Fosun Kite's CAR-T Cell Therapy Approved to be Included in the 2022 Version of Shanghai “Huhuibao”	25/05/22	PU
Shanghai Fosun Pharmaceutical : Fosun Pharma and VerImmune enter into an Exclusive License and Option Agreement for VerImmune’s Virus-inspired Particle (ViP) platform as Novel Immunotherapies in China	20/05/22	PU
Shanghai Fosun Pharmaceutical : NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS (H SHARES)	28/04/22	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Actions

600196

CNE000000X38

Communiqués

Filtres